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Aberrant activation of Wnt/b-catenin signaling is a
major driving force in colon cancer. Wnt/b-catenin
signaling induces the expression of the transcription
factor c-Myc, leading to cell proliferation and tumor-
igenesis. c-Myc regulates multiple biological pro-
cesses through its ability to directly modulate gene
expression. Here, we identify a direct target of
c-Myc, termed MYU, and show that MYU is upregu-
lated in most colon cancers and required for the
tumorigenicity of colon cancer cells. Furthermore,
we demonstrate that MYU associates with the RNA
binding protein hnRNP-K to stabilize CDK6 expres-
sion and thereby promotes the G1-S transition of
the cell cycle. These results suggest that the MYU/
hnRNP-K/CDK6 pathway functions downstream of
Wnt/c-Myc signaling and plays a critical role in the
proliferation and tumorigenicity of colon cancer cells.INTRODUCTION
The canonical Wnt signaling pathway has been implicated in
development and tumorigenesis (Bienz, 2005; Clevers and
Nusse 2012; Pronobis and Peifer, 2012). b-Catenin, a key
component of this pathway, is normally phosphorylated and tar-
geted for degradation by the destruction complex, which con-
tains Axin and the tumor suppressor adenomatous polyposis
coli (APC). Wnt stimulation releases b-catenin from the destruc-
tion complex, allowing it to accumulate and migrate to the
nucleus, where it interacts with T cell factor (TCF)/lymphoid
enhancer factor (LEF) transcription factors to stimulate the tran-
scription of Wnt target genes. The vast majority of colorectal2554 Cell Reports 16, 2554–2564, September 6, 2016 ª 2016 The Au
This is an open access article under the CC BY-NC-ND license (http://cancers are caused bymutations in APC or b-catenin, character-
ized by the stabilization of b-catenin and constitutive activation
of Wnt signaling (Anastas and Moon, 2013; Kinzler and Vogel-
stein, 1996; Polakis, 2012).
c-Myc is one of the Wnt target genes that play a critical role in
the development of colorectal cancer. c-Myc is also known to be
upregulated in multiple cancers by a variety of mechanisms,
including amplification and translocation. c-Myc is a basic he-
lix-loop-helix leucine zipper (bHLH/LZ) transcription factor that
controls the expression of up to 15% of genes in the genome
and regulates various cellular processes such as proliferation,
differentiation, and apoptosis (Bretones et al., 2015; Cole and
Cowling, 2008; Dang, 2012; Eilers and Eisenman, 2008; Kress
et al., 2015; Meyer and Penn, 2008; Pelengaris et al., 2002;
Rahl and Young, 2014; Sabo` and Amati, 2014; Schmitz et al.,
2014; van Riggelen et al., 2010; Zeller et al., 2006). Activation
of transcription by c-Myc depends on heterodimerization with
Max, which also belongs to the bHLH/LZ family. c-Myc/Max het-
erodimers bind to consensus (CACGTG) as well as to non-
consensus E-box sequences (e.g., CACATG and CATGTG) in
the regulatory regions of its targets genes (Adhikary and Eilers,
2005; Zeller et al., 2006). Furthermore, indirect recruitment of
c-Myc/Max to DNA via the zinc-finger protein Miz-1 leads to
E-box-independent repression of c-Myc-regulated genes (Wi-
ese et al., 2013; Walz et al., 2014).
In the present study, we show thatMYU, a direct target of the
Wnt/c-Myc pathway, is upregulated in most colon cancers and
required for the tumorigenicity of colon cancer cells. Further-
more, we demonstrate thatMYU associates with the RNA-bind-
ing protein heterogeneous nuclear ribonucleoprotein-K (hnRNP-
K) to stabilize cyclin-dependent kinase 6 (CDK6) expression,
thereby promoting the G1-S transition of the cell cycle. Taken
together, these results suggest that the MYU/hnRNP-K/CDK6
pathway functions downstream of Wnt/c-Myc signaling and is
crucial for colorectal tumorigenesis.thor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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RESULTS
MYU, a Direct Target of c-Myc, Is Required for the
Tumorigenicity of Colon Cancer Cells
To obtain new insights into the role of c-Myc in tumorigenesis,
we attempted to identify the target genes of c-Myc that are
responsible for cell growth. It has been reported that comparable
numbers of c-Myc-binding sites are present in non-coding genes
as well as in protein-coding genes (Cawley et al., 2004). Further-
more, it has recently been shown that a number of long non-cod-
ing RNAs (lncRNAs) play critical roles in tumor development and
progression (Batista and Chang, 2013; Yanagida et al., 2013; Ta-
niue et al., 2016). These findings raise the possibility that
lncRNAs may also play key roles in c-Myc-mediated biological
activities. Indeed, RNA sequencing (RNA-seq) analysis showed
that knockdown of c-Myc expression by small interfering RNA
(siRNA) resulted in the downregulation of 43 lncRNAs in LS180
colon cancer cells (Figure 1A; Table S1). We also found that
knockdown of b-catenin led to the downregulation of 93
lncRNAs in LS180 cells. From these data, we selected 20 over-
lapping lncRNAs as potential targets whose genes are modu-
lated by Wnt/c-Myc signaling. Furthermore, we performed
similar experiments using DLD-1 colon cancer cells and selected
11 lncRNAs as potential Wnt/c-Myc targets (Figure 1A). Compar-
ison of the data from LS180 and DLD-1 cells revealed that only
two lncRNAs are commonly upregulated in both cell lines as
potential Wnt/c-Myc targets.
Analysis of ENCODE (Encyclopedia of DNA Elements) multiple
c-Myc chromatin immunoprecipitation sequencing (ChIP-seq)
datasets revealed that c-Myc is associated with the promoter
regions (2 kb from the transcriptional start sites [TSS]) of 13
of 20 b-catenin/c-Myc target lncRNAs identified using LS180
cells (Table S1). To confirm this, we performed ChIP assays
and observed that c-Myc binds to the promoter regions of 8
of 13 b-catenin/c-Myc target lncRNAs examined, including
two lncRNAs, LOC100499227 and LC100128881, which areFigure 1. MYU Is Required for the Tumorigenicity of Colon Cancer Cel
(A) Experimental layout to identify Wnt/c-Myc target lncRNAs. The top Venn diagr
knockdown of b-catenin (green) or c-Myc (orange) in LS180 and DLD-1 cells. T
(purple) and DLD-1 (blue) cells. The number of lncRNAs within each category is
(B) Proliferation of LS180 cells transfected with the indicated siRNAs or negative co
siRNAs) or not transfected with any siRNA (no).
(C) LS180 cells infected with the indicated lentivirus were subcutaneously injecte
(D) Schematic of the MYU locus.
(E) qRT-PCR analysis of MYU expression in LS180 and DLD-1 cells transfected
(F) Left: schematic of reporter constructs used for luciferase assays. Right: LS1
sequences and subjected to luciferase assays.
(G) LS180 cells that had been treated with the indicated siRNAwere transfected w
was monitored by luciferase assay.
(H) ChIP assays were performed using anti-c-Myc antibody or rabbit immunog
nucleoplasmin (NPM) were used as positive controls. The promoter region of gl
control.
(I) qRT-PCR analysis ofMYU, c-Myc, andAxin2 expression in human colon cancer
activation.
(J) Relationship between the increases in MYU and c-Myc transcripts in colon ca
(K) qRT-PCR analysis of MYU expression in the indicated cell lines.
(L) Breast cancer cells infected with the indicated lentivirus were cultured for 7 d
(M) LS180 and SKBR3 cells were infected with the indicated lentivirus and subje
All data represent mean ± SEM (n = 3–6). *p < 0.05, **p < 0.01, ***p < 0.001.
2556 Cell Reports 16, 2554–2564, September 6, 2016commonly upregulated in both LS180 and DLD-1 cells (Fig-
ure S1A; Table S1).
We then examined the potential role of these two lncRNAs in
the proliferation of colon cancer cells. We found that siRNA
knockdown of one of the two lncRNAs, termed MYU (c-Myc-
upregulated lncRNA, LOC100128881, NCBI: NR_036480.1),
resulted in reduced proliferation of LS180 cells (Figure 1B).
We infected LS180 cells with a lentivirus expressing a short
hairpin RNA (shRNA)-targeting MYU and transplanted these
into nude mice. The growth of these tumor cells was markedly
retarded compared with tumor cells infected with control virus
(Figures 1C, S1B, and S1C). In parallel experiments, knock-
down of either b-catenin or c-Myc also resulted in reduced
proliferation and tumorigenicity of LS180 cells. These results
suggest that MYU is required for the tumorigenicity of colon
cancer cells. Thus, we focused our analysis on the function
of MYU.
MYU is generated from the opposite strand of the VPS9D1
gene (Figure 1D). RT-PCR analysis revealed that the majority of
the MYU transcripts were localized in the cytoplasm (Figures
S1D and S1E). We first confirmed that knockdown of b-catenin
or c-Myc led to reductions in the amounts of MYU in LS180
and DLD-1 colon cancer cells (Figure 1E). To clarify the mecha-
nisms underlying c-Myc-mediated upregulation ofMYU, we per-
formed luciferase assays with reporter constructs containing
various fragments of the MYU promoter region. Deletion of one
of the two E-boxes (E-box-1 in Figure 1F) did not have any signif-
icant effect on promoter activity, butmutations in the other E-box
(E-box-2) caused a reduction in activity (Figure 1F). Inclusion of
the region between631 and78 led to a decrease in luciferase
activity, suggesting that a negative regulatory element(s) is pre-
sent in this region. Furthermore, knockdown of c-Myc reduced
the activity of a promoter region containing wild-type (WT) but
not mutated (Mut) E-box-2 (Figure 1G). In addition, ChIP assays
showed that c-Myc specifically associated with this region
(Figures 1H and S1F), which is also associated with highlyls
ams represent the overlap of lncRNAs downregulated (>2-fold, FPKM >0.5) by
he bottom Venn diagram shows target lncRNAs of b-catenin/c-Myc in LS180
indicated.
ntrols (control-1 forMYU siRNAs and control-2 for b-catenin [b-cat] and c-Myc
d into nude mice (n = 8/group).
with the indicated siRNA.
80 cells were transfected with reporter constructs containing MYU promoter
ith anMYU reporter construct containing eitherWT orMut E-box-2, and activity
lobulin G (IgG). The promoter regions of ornithine decarboxylase (ODC) and
yceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a negative
tissues (n = 28 pairs).Axin2was used as amarker of b-catenin-TCF4-mediated
ncer.
ays, and the number of cells was counted.
cted to colony formation assays in soft agar.
trimethylated histone H3 lysine 4 (H3K4me3) (Figures S1F and
S1G). Thus, c-Myc may directly upregulate the transcription of
MYU by binding to E-box-2, the sequence of which (CACATG)
is identical to that of the non-consensus c-Myc-binding motif.
Taken together, these results suggest thatMYU is a direct target
of Wnt/c-Myc signaling in colon cancer cells.
MYU Plays a Critical Role in c-Myc-Dependent
Proliferation
Consistent with the above results,MYU expression was upregu-
lated in human colorectal cancer specimens, similar to c-Myc
and Axin2 expression (Figure 1I). We also detected a significant
correlation between increasedMYU and c-Myc transcript levels
in cancers (Figure 1J), although no significant relationship was
detected between MYU expression and histological grade/
prognosis (data not shown). MYU was also highly expressed
in colorectal cancer cell lines compared with normal colon-
derived fibroblast cells (Figure 1K). We also found that knock-
down of MYU barely affected the growth of CCD-112CoN
normal colon fibroblast cells (Figures S1H and S1I). Thus,
MYU may play an essential role in tumor cells overexpressing
c-Myc.
To confirm this possibility, we examined the effect of MYU
knockdown on the growth of two types of breast cancer cell
lines that express high levels or low levels of c-Myc. It has
been shown that knockdown of c-Myc results in a significant
reduction in the growth of breast cancer cells overexpressing
c-Myc, such as SKBR3 andMDA-MB-453 cells, but had little ef-
fect on cells expressing c-Myc at low levels, such as BT20 and
MDA-MB-157 cells (Kang et al., 2014). In line with these results,
we found that MYU as well as c-Myc were highly expressed in
SKBR3 and MDA-MB-453 cells compared with BT20 and
MDA-MB-157 cells (Figures 1K and S1J). Knockdown of either
MYU or c-Myc resulted in growth inhibition of only SKBR3 and
MDA-MB-453 cells (Figures 1L, S1K, and S1L). Colony forma-
tion assays with LS180 and SKBR3 cells in soft agar showed
that knockdown of either MYU or c-Myc caused a significant
reduction in their clonogenicity (Figure 1M). These results sug-
gest that MYU plays a critical role in c-Myc-dependent
proliferation.
Identification of CDK6 as a Target of the Wnt/c-Myc/
MYU Pathway
To identify target molecules downstream in theWnt/c-Myc/MYU
pathway, we used siRNA to suppress b-catenin, c-Myc, orMYU
expression in LS180 and DLD1 cells and then examined their
gene expression profiles. DNAmicroarray and gene ontology an-
alyses indicated that the target genes regulated in common by
Wnt, c-Myc, and MYU were enriched for those involved in cell-
cycle phase and cell-cycle process (Figure 2A). Notably, qRT-
PCR and immunoblotting analyses revealed that the expression
of CDK6 was reduced in all of these cells (Figures 2B–2E). We
also observed decreased phosphorylation of the retinoblastoma
(Rb) protein at Ser807/811, the target sites of CDK6, in LS180
cells in which b-catenin, c-Myc, or MYU had been knocked
down (Figure S2A). Furthermore, we found that overexpression
of MYU partially restored CDK6 expression in LS180 cells in
which either b-catenin or c-Myc had been knocked down (Fig-ures 2F and S2B). In addition, overexpression of c-Myc did not
affect CDK6 expression in HCT116 colon cancer cells in which
MYU had been knocked down (Figures S2C and S2D). These re-
sults suggest that the Wnt/c-Myc/MYU pathway has the poten-
tial to upregulate CDK6 expression.
MYU Interacts with hnRNP-K to Stabilize CDK6
Expression
To investigate the mechanisms underlying MYU-mediated up-
regulation of CDK6, we sought to identify proteins associated
with MYU by RNA pull-down experiments. Proteins co-precip-
itated with a biotinylated MYU transcript were separated by
SDS-PAGE and analyzed by mass spectrometry (Figure 3A; Ta-
ble S2). We identified eight candidate binding proteins and
examined whether knockdown of each of their genes by siRNA
affected CDK6 expression. Among these genes, knockdown of
hnRNP-K caused the most significant decrease in CDK6
expression (Figures 3B and 3C). Moreover, knockdown of
hnRNP-K or CDK6 reduced the growth and tumorigenicity of
LS180 cells (Figures S3A–S3D). Immunoblotting analysis re-
vealed that hnRNP-K was specifically associated with the
sense strand of MYU (Figure 3D). Furthermore, RNA immuno-
precipitation (RIP) analysis showed that endogenous MYU
was associated with hnRNP-K (Figure 3E). In addition, deletion
mapping experiments showed that fragments of the MYU tran-
script containing nucleotides 396–1,410 or 852–1,753 were
capable of binding to hnRNP-K (Figure 3D). Consistent with
this result, these regions, especially nucleotides 852–1,753,
contain multiple cytidine-uridine (CU)-rich elements that are
potential consensus binding sites for hnRNP-K (Matunis
et al., 1992; Ostareck et al., 1997).
hnRNP-K contains multiple RNA recognition motifs and is
involved in transcription, RNA splicing, mRNA stability, and
translation. hnRNP-K plays an important role in the mitotic pro-
cess and proliferation of colon cancer cells (Sugimasa et al.,
2015). hnRNP-K is normally localized exclusively in the nucleus
in normal colon tissues but is found in both the cytoplasm
and nucleus in colon cancer cells (Carpenter et al., 2006).
Although extracellular signal-regulated kinase (ERK)-dependent
phosphorylation of hnRNP-K triggers its accumulation in the
cytoplasm (Habelhah et al., 2001), we found that ectopic overex-
pression of MYU did not affect the localization of hnRNP-K in
CCD-112CoN normal colon cells.
We examined whether the MYU-hnRNP-K complex interacts
with CDK6 mRNA and regulates its expression via a posttran-
scriptional mechanism. RIP analysis revealed that hnRNP-K is
associated with CDK6 mRNA in vivo (Figure 3E). RNA pull-
down assays revealed that hnRNP-K could bind to nucleotides
7558–7,989 in the CDK6 30 UTR (WT-30 UTR), which contains
three CU-rich elements, designated CU-rich elements 2, 3, and
4 (Figures 3F and 3G). Furthermore, mutations in CU-rich
element 2 (Mut1- and Mut2-30 UTR), but not in CU-rich element
3 (Mut3-30 UTR) caused a reduction in binding activity. Mutations
in CU-rich element 4 (Mut4-30 UTR) led to a slight decrease
in binding activity. Thus, hnRNP-K may directly interact with
CDK6 mRNA mainly through CU-rich element 2. In addition,
RNA pull-down assays followed by qRT-PCR analysis revealed
that MYU co-precipitated with the CDK6 WT-30 UTR but notCell Reports 16, 2554–2564, September 6, 2016 2557
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Figure 2. Identification of CDK6 as a Target of the Wnt/c-Myc/MYU Pathway
(A) Microarray analysis ofMYU-, b-catenin-, and c-Myc-regulated genes in LS180 cells. Left: Venn diagram showing the overlap of genes downregulated byMYU
(blue), b-catenin (green), or c-Myc (orange) knockdown. The number of genes within each category is indicated. Right: gene ontology analysis of the genes shared
by the MYU, b-catenin, and c-Myc signatures.
(B–E) qRT-PCR (B, D, and E, bottompanel) and immunoblotting (C and E, top two panels) analyses of CDK6 expression in LS180 andDLD-1 cells transfectedwith
the indicated siRNA. Results are expressed as the mean ± SEM (n = 3–4). **p < 0.01, ***p < 0.001.
(F) Immunoblotting analysis of CDK6 expression in LS180 cells. Lentiviral expression ofMYU restores expression of CDK6 in b-catenin or c-Myc knockdown cells.the Mut1-30 UTR (Figure 3H). We also found that knockdown of
MYU or c-Myc reduced the amount of CDK6 that co-immuno-
precipitated with hnRNP-K (Figures 3I–3K). By contrast, knock-
down of MYU barely affected the binding of hnRNP-K to other
target RNAs,MYCLo-2 andCDKN1A (Kim et al., 2015; Figure 3I).
These results suggest thatMYU and c-Myc promote the recruit-
ment of hnRNP-K to the CDK6 mRNA. Comparison of the se-
quences of MYU and Cdk6 mRNA excludes their direct base-
pairing. Thus, the detailed molecular mechanisms by which the
MYU/hnRNP-K complex recognizes the Cdk6 mRNA remain to
be investigated.2558 Cell Reports 16, 2554–2564, September 6, 2016We performed qRT-PCR analysis to measure the expression
levels ofMYU and hnRNP-K and found that the approximate cy-
cle numbers of MYU, hnRNP-K, and Actin in LS180 cells were
24, 20, and 15, respectively. Thus, the expression level of
MYUmay be much lower than that of hnRNP-K. This result sug-
gests that MYU could be a limiting factor for the interaction be-
tween MYU and hnRNP-K.
We next examined whether the seven other candidate MYU-
binding proteins are present in the MYU-hnRNP-K complex.
When lysates from LS180 cells were subjected to immunoprecip-
itation with anti-hnRNP-K antibody followed by immunoblotting
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Figure 3. MYU Interacts with hnRNP-K to Stabilize CDK6 Expression
(A) Proteins from HT29 cell lysates were subjected to RNA pull-down assays using biotinylated full-lengthMYU (MYU-full) or its antisense RNA (negative control)
and analyzed by SDS-PAGE followed by silver staining. The band specific to MYU was cut out and identified by mass spectrometry.
(legend continued on next page)
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with antibodies against the seven proteins, FUBP3 and IGF2BP2
were found to co-immunoprecipitate with hnRNP-K (Figure S3E;
Table S2). However, knockdown of FUBP3 and IGF2BP2 as well
as other candidate proteins barely affected the viability of LS180
cells (Figure S3F).
miR-15a and miR-16 share a common seed sequence and
are known to have tumor suppressor activity. Overexpression
of miR-15a or miR-16 mimics reduced CDK6 expression (Fig-
ure S3G), as reported previously (Liu et al., 2008). Conversely,
inhibition of miR-16, but not of miR-15a, resulted in increased
expression of CDK6 in SW480 colon cancer cells (Figure S3H).
In contrast to a previous report (Liu et al., 2008), the miRNA
target prediction algorithm TargetScan indicated that CDK6
harbors one well conserved miR-15a/16 binding site at nucleo-
tides 7,881–7,887 in its 30 UTR. Overexpression of a miR-16
mimic resulted in decreased activity of a reporter construct
containing the wild-type, but not mutant, miR-15a/16 seed
sequence (Figures 3F and S3I). These results suggest that
miR-16 has the potential to suppress CDK6 expression by
directly binding to the conserved miR-15a/16 binding site in
the CDK6 30 UTR.
It has been reported that the expression of COX-2 and seroto-
nin transporter (SERT) is suppressed by miR-16 and that this
suppression is antagonized by hnRNP-K binding to sites adja-
cent to the miR-16-binding sites in the 30 UTRs of these genes
(Shanmugam et al., 2008; Yoon et al., 2013). Because the miR-
15a/16 target site in the CDK6 30 UTR resides adjacent to the
CU-rich elements 24 (Figure 3F), we examined the effect of
hnRNP-K expression on the miR-16-mediated inhibition of
CDK6 expression. We found that overexpression of hnRNP-K
orMYU suppressed the inhibitory effect of miR-16 on the activity
of the luciferase reporter containing the miR-15a/16 binding site
(Figure S3J). These results raise the possibility that hnRNP-K and
MYUmay interfere with the interaction of the miR-16-Ago2 com-
plex with the miR-15a/16 binding site. We therefore performed
RNA-binding protein pull-down assays.WhenmiR-16was trans-
fected into LS180 cells, Ago2 was found to co-precipitate with
the CDK6 WT-30 UTR but not the Mut5-30 UTR (Figure S3K).
Furthermore, we found that knockdown of hnRNP-K led to an
increase in the amount of Ago2 co-precipitated with the CDK6
WT-30 UTR in the presence of miR-16. These results suggest
that hnRNP-K inhibits the interaction of the miR-16-Ago2 com-
plex with the miR-16 target site in the CDK6 30 UTR.(B and C) qRT-PCR (B) and immunoblotting (C) analyses of CDK6 expression in
(D) Top: schematic of the full-length and deletion fragments of MYU used for th
antisense transcript. ++ and +, detectable binding activity; , no detectable act
shown.
(E) RIP assays were performed on LS180 and DLD-1 cells using anti-hnRNP-K a
controls. CDKN1A was used as a positive control.
(F) Schematic of the CDK6 mRNA and constructs used for RNA pull-down exper
(G) Lysates from DLD-1 cells were incubated with biotinylated wild-type and m
immunoblotting analysis with anti-hnRNP-K antibody.
(H) Lysates from LS180 andDLD-1 cells were incubatedwith biotinylatedwild-type
qRT-PCR. HPRT1 and NEAT1 were negative controls.
(I and J) The amounts of the hnRNP-K-CDK6mRNA complexes are decreased in
RIP assays were performed using anti-hnRNP-K (K) antibody or mouse IgG.
(K) Immunoblotting analysis of the immunoprecipitates using an anti-hnRNPK
***p < 0.001.
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Essential for Cell Cycle Progression and Clonogenicity
CDK6 is known to play an important role in facilitating progres-
sion through G1 phase of the cell cycle. To address the signif-
icance of Wnt/c-Myc- and MYU/hnRNP-K-induced CDK6 ex-
pression in the cell cycle, LS180 cells were transfected with
siRNA to knock down expression of each of several genes,
cultured in the presence of nocodazole, which prevents re-en-
try of cells into G1 phase, and then stained with propidium
iodide (PI) and analyzed by fluorescence-activated cell sorting
(FACS). In cells transfected with MYU siRNA, there was a sig-
nificant increase in the G1 cell population (Figure 4A), consis-
tent with arrest in G1 phase. This indicates that MYU may be
required for the G1/S transition. We obtained similar results
with cells transfected with siRNA targeting b-catenin, c-Myc,
hnRNP-K, or CDK6 (Figure S4A), consistent with previous re-
ports (Sherr, 1993; Tang et al., 2014). We also found that over-
expression of MYU could partially rescue cell-cycle progres-
sion in c-Myc knockdown cells (Figure 4B). Furthermore,
although knockdown of MYU, b-catenin, c-Myc, or hnRNP-K
by siRNA caused an increase in the fraction of LS180 cells in
G1, as shown above, concomitant overexpression of CDK6
suppressed this increase and partially restored cell-cycle pro-
gression (Figures 4C, 4D, and S4B). We also performed long-
term colony formation assays with the FLAG-tagged CDK6
coding sequence fused to its 30 UTR fragment (nucleotides
7,558–7,989, shown in Figure 3F) that contains either wild-
type (WT-30 UTR) or mutated (Mut1-30 UTR) MYU/hnRNP-K
binding sites. We found that overexpression of the CDK6-
WT-30 UTR, but not of the CDK6-Mut1-30 UTR, partially
restored the colony-forming capacity of LS180 cells in which
c-Myc had been knocked down (Figure 4E). These results
suggest that Wnt/c-Myc- and MYU/hnRNP-K-mediated upre-
gulation of CDK6 is essential for cell-cycle progression and
clonogenicity.
It has been shown that CDK4 is a direct target of c-Myc
(Hermeking et al., 2000) and that it regulates G1 progression.
Therefore, we next examined the relationship between the
MYU/hnRNP-K/CDK6 pathway and the CDK4 pathway in
c-Myc-mediated G1 progression. The effect of b-catenin or
c-Myc knockdown on G1 arrest was more significant than
that observed with CDK4, MYU, or CDK6 knockdown (Fig-
ure 4F; Figures S4C and S4D). Furthermore, double knockdownLS180 and DLD-1 cells transfected with the indicated siRNAs.
e precipitation of hnRNP-K from DLD-1 cell lysates. Se, sense transcript; AS,
ivity. Bottom: precipitated hnRNP-K and biotin-labeled fragments of MYU are
ntibody or mouse IgG. HPRT1 and the lncRNA NEAT1 were used as negative
iments (G and H) and luciferase assays (Figures S3I and S3J).
utant fragments of the CDK6 30 UTR, and bound proteins were analyzed by
andmutant fragments of theCDK6 30 UTR, and bound RNAswere analyzed by
LS180 and DLD-1 cells in whichMYU (I) or c-Myc (J) had been knocked down.
antibody. All data represent mean ± SEM (n = 3–4). *p < 0.05, **p < 0.01,
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Figure 4. Wnt/c-Myc/MYU-Mediated Upregulation of CDK6 Is Essential for Cell-Cycle Progression
(A) LS180 cells were transfected with the indicated siRNA, and cell-cycle distribution was analyzed by FACS.
(B) Lentiviral MYU partially rescues G1 progression of LS180 cells in which c-Myc had been knocked down.
(C and D) Exogenous expression of CDK6 restores G1 progression of LS180 cells in which eitherMYU (C), b-catenin, c-Myc, or hnRNP-K (D) had been knocked
down.
(E) Colony-forming ability of LS180 cells infected with a lentivirus expressing the FLAG-tagged CDK6 coding sequence fused to its 30 UTR fragment (nucleotides
7,558–7,989) that contains either aWT or MutMYU/hnRNPK binding site along with a lentivirus expressingMYU or shRNA targeting c-Myc. Top: immunoblotting
analysis of FLAG-tagged CDK6 and c-Myc expression.
(F) LS180 cells were transfected with the indicated siRNAs and subjected to cell-cycle analysis by FACS.
(G) Model of Wnt/c-Myc/MYU-induced tumorigenesis. Wnt/c-Myc signaling directly enhances MYU expression. MYU forms a complex with hnRNP-K and
stabilizes CDK6 expression by suppressing the inhibitory effect of miR-16 and thereby facilitates cell-cycle progression. TheMYU/hnRNP-K/CDK6 pathway and
the CDK4 pathway may contribute independently to Wnt/c-Myc-induced cell-cycle progression.
All data represent mean ± SEM (n = 3–10). *p < 0.05, **p < 0.01, ***p < 0.001.
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of CDK4/MYU led to increased G1 arrest comparable with that
obtained by c-Myc knockdown; thus, the effect of knocking
down CDK4 and MYU appears to be additive. Therefore, the
MYU/hnRNP-K/CDK6 pathway and the CDK4 pathway may
contribute independently to Wnt/c-Myc-mediated cell-cycle
progression.
DISCUSSION
c-Myc is one of the most commonly activated oncogenes
and is estimated to be involved in 20% of all human cancers
(Dang et al., 2006). Thus, much effort has been devoted to
understanding the molecular mechanisms underlying the role
of c-Myc in cell-cycle control. It has been shown that c-Myc-
induced cell proliferation is generally associated with an in-
crease in CDK4 and CDK6 activities, which regulate G1 pro-
gression (Mateyak et al., 1999). It has also been reported
that c-Myc induces the expression of CDK4 by directly binding
to the CDK4 promoter region (Hermeking et al., 2000). Gene
profiling studies have shown that c-Myc regulates the expres-
sion of CDK6 mRNA (Yap et al., 2011). In the present study, we
identified MYU as a direct target gene of the Wnt/c-Myc
pathway and showed that Wnt/c-Myc/MYU-mediated upregu-
lation of CDK6 is essential for cell-cycle progression of colon
cancer cells (Figure 4G).
Although the Wnt/b-catenin signal and c-Myc drive multiple
downstream targets, we found that ectopic CDK6 is able to
partially restore G1/S cell-cycle progression in LS180 cells in
which b-catenin or c-Myc had been knocked down (Figure 4D).
Consistent with this finding, the effect of CDK6 knockdown on
G1 arrest was more significant than that observed with CDK4
knockdown (Figure 4F), suggesting that CDK6 functions as a
major mediator in LS180 cells. We also observed that LS180
cells express high levels of cyclin D1 but low/moderate levels
of cyclin D2 and D3, and knockdown of c-Myc did not result in
critical reductions in the expression of any of the D-type cyclins
(Figure S4E), although cyclin D2 has been reported to be a direct
target of c-Myc (Bouchard et al., 1999). Furthermore, we found
that knockdown of b-catenin did not reduce the expression of
cyclin D1, a well-known Wnt/b-catenin target, in LS180 cells
(Figure S4F). These results are consistent with the notion that
Wnt/c-Myc/MYU-mediated upregulation of CDK6 may play an
important role in the proliferation and tumorigenicity of some co-
lon cancer cells.
Tumorigenesis assays showed that c-Myc knockdown cells
grew more slowly than b-catenin knockdown cells. The mecha-
nisms underlying this different tumorigenic activity between
b-catenin and c-Myc remain to be elucidated. We speculate
that some of the b-catenin target genes other than c-Myc may
negatively affect the growth of colon cancer cells.
It is well known that c-Myc functions downstream of many
signal transduction pathways, serving as a central organizer
that integrates multiple intracellular and extracellular cues. In
addition to cancer, previous studies have shown that c-Myc
is implicated in many diseases, including inflammation (Pap
et al., 2004; Weng et al., 2006) and cardiovascular diseases
(Ahuja et al., 2010). It has also been reported that the role of
c-Myc in pluripotency is related to its ability to regulate the2562 Cell Reports 16, 2554–2564, September 6, 2016cell-cyclemachinery (Singh andDalton, 2009). Thus, our findings
may have implications beyond cancer and apply to other dis-
eases and to stem cell biology. Understanding the molecular de-
tails of MYU/hnRNP-K cooperation may provide a basis for the
rational development of novel drugs to treat some cancers and
other diseases.
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